Company intelligence / Profile preview
Cerecin
Denver, Colorado, United Statescerecin.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Cerecin’s lead asset CER‑0001 has shown promising pilot data in migraine and infantile spasms. The company recently expanded its pipeline with CER‑022, a novel PET imaging agent to study ketone body metabolism. Their focus on neurometabolism positions them at the forefront of developing therapies that address metabolic dysfunctions underlying CNS diseases.[3][5]
- Therapeutic areas
- Neurology
- Modalities
- Small molecules (notably lipid-based therapeutics such as tricaprilin)Diagnostic radiotracers (e.g., [18F]FBHB for PET imaging)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Nestlé S.A.Wilmar International LimitedUniversity of Alberta (licensing partner)[4][5]
Beyond the preview
Go deeper on Cerecin.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cerecin.